Literatur
-
1
Scandinavian Simwastatin Survival Study Group .
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
Lancet.
1994;
344
1383-1389
-
2
Sacks F M, Pfeffer M A, Moye L A, rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J MO, Wun C C, Davis B R, Braunwald E. for the Cholesterol and Recurrent Events Trial Investigators .
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med.
1996;
335
1001-1109
-
3
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group .
Prevention of cardiovascular events and death with pravastatin in patients with coronary heard disease and a broad range of initial cholesterol levels.
N Engl J Med.
1998;
339
1349-1357
-
4
Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, Macfarlane P W, MkKillop J H, Packard C J. for the West of Scotland Coronary prevention study Group .
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med.
1995;
333
1301-1307
-
5
Burkhard-Meier C, Deutsch H J, Erdmann E.
Aktuelle Therapie der instabilen Angina pectoris.
Dtsch med Wschr.
1999;
124
733-739
-
6
Pitt B, Waters D, Brown W V, van Boven A J, Schwartz L, Title L M, Eisenberg D, Shurzinske L, McCormick L S. for the Atorvastatin versus Revascularization Treatment Investigators .
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
N Engl J Med.
1999;
341
70-76
-
7
Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco A V, Litarru G P.
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study.
J Clin Pharmacol.
1993;
33
226-229
-
8
Watts G F, Castelluccio C, Rice-Evans C, Taub N A, Baum H, Quinn P J.
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
J Clin Pathol.
1993;
46
1055-1057
-
9
De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc J L, Astier A, Jacotot B, Cherardi R.
Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio.
Brit J Clin Pharmacol.
1996;
42
333-337
-
10
Human J A, Ubbink J B, Jerling J J, Delport R, Vermaak W J, Vorster H H, Lagendijk J, Potgieter H C.
The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
Clin Chim Acta.
1997;
263
67-77
-
11
Mortensen S A, Leth A, Agner E, Rohde M.
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Mol Asp Med.
1997;
18 (Suppl.)
S137-144
-
12
Steering committee of the Physician’s Health Study Research Group .
Final report on the aspirin component of the ongoing Physician’s Health Study.
N Engl J Med.
1989;
296
313-316
-
13
Stephens N G, Parsons A, Schofield P M, Kelly F, Cheeseman K, Mitchinson M J.
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).
Lancet.
1996;
347
781-786
-
14
Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thomson E, Norton S. et al .
Randomised trial of prophylactic daily aspirin in British male doctors.
Brit Med J.
1988;
296
313-316
Prof. Dr. Dr. Hanns-Ulrich Marschall
Karolinska Institutet Dept. of Medicine Div. of Gastroenterology and Hepatology Huddinge University Hospital K63
14 86 Stockholm
Schweden
Email: hanns-ulrich.marschall@mbb.ki.se
